

IMMUNOGEN INC  
Form 3  
May 19, 2016

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Enyedy Mark J

(Last) (First) (Middle)

24 CONCORD SQUARE

(Street)

BOSTON, MA 02118

(City) (State) (Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

05/16/2016

3. Issuer Name and Ticker or Trading Symbol  
IMMUNOGEN INC [IMGN]

4. Relationship of Reporting  
Person(s) to Issuer

(Check all applicable)

☒ Director ☐ 10% Owner

☒ Officer ☐ Other  
(give title below) (specify below)

Chief Executive Officer

5. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting  
Person

☐ Form filed by More than One  
Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

75,100 <sup>(1)</sup>

D

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative  
Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

Date Exercisable Expiration  
Date

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

Title Amount or  
Number of

4. Conversion  
or Exercise  
Price of  
Derivative  
Security

5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)  
or Indirect

6. Nature of Indirect  
Beneficial  
Ownership  
(Instr. 5)

# Edgar Filing: IMMUNOGEN INC - Form 3

|                             |                           |            |              |         |         |            |   |
|-----------------------------|---------------------------|------------|--------------|---------|---------|------------|---|
|                             |                           |            |              | Shares  |         | (I)        |   |
|                             |                           |            |              |         |         | (Instr. 5) |   |
| Stock Option (right to buy) | 05/16/2017 <sup>(2)</sup> | 05/16/2026 | Common Stock | 300,000 | \$ 5.65 | D          | Â |

## Reporting Owners

| Reporting Owner Name / Address                         | Relationships |           |                           |       |
|--------------------------------------------------------|---------------|-----------|---------------------------|-------|
|                                                        | Director      | 10% Owner | Officer                   | Other |
| Enyedy Mark J<br>24 CONCORD SQUARE<br>BOSTON, MA 02118 | Â X           | Â         | Â Chief Executive Officer | Â     |

## Signatures

/s/ Craig Barrows, attorney  
in fact

05/19/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 75,000 of these shares are restricted stock which vest annually in four equal installments commencing on May 16, 2017.

(2) Exercisable as to 75,000 shares commencing on May 16, 2017, 75,000 shares commencing on May 16, 2018, 75,000 shares commencing on May 16, 2019 and 75,000 shares commencing on May 16, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.